These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38555681)

  • 1. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
    Ornstein MC; Wood L; Elson P; Allman K; Beach J; Martin A; Gilligan T; Garcia JA; Rini BI
    Clin Genitourin Cancer; 2017 Apr; 15(2):e275-e280. PubMed ID: 27625016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.
    Krens SD; Mulder SF; van Erp NP
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):271-274. PubMed ID: 34853912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma.
    Takasaki S; Kawasaki Y; Kikuchi M; Ito A; Yamaguchi H; Mano N
    J Pharm Pharm Sci; 2021; 24():127-136. PubMed ID: 34559626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
    Del Re M; Crucitta S; Brighi N; Kinspergher S; Mercinelli C; Rizzo M; Conteduca V; Rebuzzi SE; Beninato T; Venturi G; Doni L; Verzoni E; Puglisi S; Landriscina M; Porta C; Manfredi F; Caffo O; De Giorgi U; Fogli S; Danesi R
    Clin Genitourin Cancer; 2024 Oct; 22(5):102147. PubMed ID: 39030142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review.
    Demlová R; Turjap M; Peš O; Kostolanská K; Juřica J
    Ther Drug Monit; 2020 Feb; 42(1):20-32. PubMed ID: 31259881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.
    Majidova N; Seyyar M; Bayraktar DI; Dinç G; İsgandarov E; Huseynov J; Yaşar A; Çelebi A; Sever N; Kocaaslan E; Erel P; Ağyol Y; Güren AK; Arıkan R; Işık S; Ercelep Ö; Demirağ G; Kefeli U; Köstek O; Bayoğlu İV; Sarı M
    Biomol Biomed; 2024 Oct; 24(6):1776-1784. PubMed ID: 38920621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
    Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma.
    Beinse G; Hulin A; Rousseau B
    Invest New Drugs; 2019 Dec; 37(6):1289-1291. PubMed ID: 30806848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
    Manz KM; Fenchel K; Eilers A; Morgan J; Wittling K; Dempke WCM
    Adv Ther; 2020 Feb; 37(2):730-744. PubMed ID: 31838709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Keil C; Götze L; Olbert P; Hofmann R; Nockher WA; Hegele A
    Urologe A; 2015 Jun; 54(6):811-8. PubMed ID: 25503897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.